Immunic Strengthens Leadership with Dr. Michael A. Panzara as Chief Medical Officer

Immunic's New Era with Dr. Michael A. Panzara as Chief Medical Officer

Immunic, Inc., a late-stage biotechnology firm known for its innovative oral therapies for neurological issues, has recently appointed Dr. Michael A. Panzara as its new Chief Medical Officer, effective April 24, 2026. This strategic move is significant for the company as it aims to enhance its clinical strategy amid a transformative stage in its development pipeline.

Dr. Panzara brings a wealth of experience to Immunic, accumulated over 25 years in the neurology sector. Noteworthy among his accomplishments is his previous leadership role at Sanofi Genzyme, where he successfully oversaw the regulatory approvals of leading multiple sclerosis (MS) therapies, including LEMTRADA® and AUBAGIO®. His extensive background will be invaluable as Immunic progresses with vidofludimus calcium, a promising treatment currently awaiting pivotal phase 3 trial results for relapsing MS.

As the Chief Medical Officer, Dr. Panzara will not only lead Immunic's clinical development initiatives but also collaborate closely with the CEO and the Board of Directors to shape the company’s overarching strategy. Immunic’s CEO, Dr. Daniel Vitt, expressed confidence in Dr. Panzara's abilities, noting his deep knowledge in drug development and regulatory processes. This expertise is critical for guiding vidofludimus calcium through the next stages of clinical development as the company gears up for potential regulatory approval and commercialization.

In his own address, Dr. Panzara emphasized the critical nature of his appointment, acknowledging the immense potential of vidofludimus calcium to revolutionize MS treatment. He expressed enthusiasm for building upon the company’s achievements and advancing forthcoming clinical trials, including those slated for primary progressive MS.

Prior to this role, Dr. Panzara served as the Chief Medical Officer for Neurvati Neurosciences, where he was instrumental in assembling a development organization to enhance therapeutic candidates for neurological and psychiatric disorders. He also led the therapeutics development at Wave Life Sciences, with a focus on genetically defined neurological conditions, further showcasing his capability in advancing biological therapies.

Dr. Panzara's academic foundations are robust, with a bachelor's degree from the University of Pennsylvania, a medical degree from Stanford University School of Medicine, and a Master of Public Health from Harvard. His training includes neurology residency at Massachusetts General Hospital and postdoctoral studies in immunology at Brigham and Women’s Hospital, affirming his strong clinical and research capabilities.

The leadership transition comes as Immunic thanks its former CMO, Dr. Andreas Muehler, highlighting his pivotal role in elevating vidofludimus calcium to its current advanced stage. Dr. Muehler will remain involved with the company as a consultant, ensuring continuity and leveraging his extensive knowledge of the ongoing projects.

Looking ahead, Immunic is poised to make substantive impacts in the MS treatment landscape, particularly with the anticipated results from the phase 3 ENSURE trials and the extension of their therapeutic pipeline with other compounds like IMU-856 and IMU-381. These efforts reflect Immunic's commitment to tackling challenging neurological and autoimmune disorders through cutting-edge research and development.

The potential of vidofludimus calcium stands as a beacon of hope for many suffering from the debilitating effects of MS. As Dr. Panzara assumes his new role, the passion for transforming therapy strategies into improved patient outcomes is palpable, promising a hopeful future for numerous patients battling neurological diseases.

For more information about Immunic and its initiatives, visit Immunic’s website.